Prediction of the Thromboembolic Syndrome: an Application of Artificial Neural Networks in Gene Expression Data Analysis

The aim of this study was to propose a method for improving the power of recognition and classification of thromboembolic syndrome based on the analysis of ‎ gene expression data using artificial neural networks. The studied method was performed on a dataset which contained data about 117 patients admitted to a hospital in Durham in 2009. Of all the studied patients, 66 patients were suffering from thromboembolic syndrome and 51 people were enrolled in the study as the control group. The gene expression level of 22277 was measured for all the samples and was entered into the model as the main variable. Due to the high number of variables, principal components analysis and auto-encoder neural network methods were used in order to reduce the dimension of data. The results showed that when using auto-encoder networks, the classification accuracy was 93.12. When using the PCA method to reduce the size of the data, the obtained accuracy was 78.26, and hence a significant difference in the accuracy of classification was observed. If auto-encoder network method is used, the sensitivity and specificity will be 92.58 and 93.68 and when PCA method is used, they will be 0.77 and 0.78 respectively. The results suggested that auto-encoder networks, compared with the PCA method, had a higher level of accuracy for the classification of thromboembolic syndrome status

Fanconi anemia phenotypic and transplant outcomes' associations in Iranian patients

Abstract Objectives Fanconi anemia (FA) is a rare, heterogeneous, inherited disorder. Allogeneic hematopoietic stem cell transplantation (HSCT) represents the only therapeutic option to restore normal hematopoiesis. This study reports the outcomes of FA‐HSCT patients and identifies factors, including clinical phenotype. Our team examined more than 95% of Iranian FA patients during the last decade. Study Design One hundred and six FA patients (age range: 2–41) who underwent HSCT from March 2007 to February 2018 were enrolled. Clinical characteristics of genetic disease, pre‐HSCT findings, HSCT indication, and long‐term follow‐up evaluated and recorded. Data were analyzed using SPSS 19.0. Results The mean follow‐up period for survivors was 36 months (range, 1–101). The 3‐year overall survival (OS) and disease‐free survival were 72.2% and 71.2%, respectively. The 3‐year OS rate for patients with limited and extensive malformations was 78.8% and 56.6%, respectively (p = 0.025). Acute graft versus host disease incidence was 60.52% for patients with limited malformations versus 70% for patients with extensive ones (p = 0.49). Chronic graft versus host disease incidence for these two groups was 9.21% and 10%, respectively (p = 0.91). Conclusions OS was not associated with each of the malformations singly; however, it was lower in the extensive group. The younger age of patients at the HSCT time leads to a higher OS. The differences in FA patients' outcomes and the various genotypes were probably related. These data provide a powerful tool for further studies on genotype–phenotype association with HSCT results